AIM
DNLI icon

Axiom Investment Management’s Denali Therapeutics DNLI Stock Holding History

Axiom Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-168
Closed -$377 – 200
2020
Q4 		$377 Buy
+168
New +$10.2K 0.34% 71

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axiom Investment Management's DNLI Position: Q1 2021 in Review

Axiom Investment Management sold out of Denali Therapeutics (DNLI) in Q1 2021, closing a stake of 168 shares — an estimated $377 sold.

Axiom Investment Management first reported a position in DNLI in Q4 2020 and held it in 1 quarter. The position peaked at $377 in Q4 2020. 216 funds tracked by Wall St. Rank hold DNLI as of Q1 2021.

  • Axiom Investment Management reported no remaining Denali Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Axiom Investment Management sold 168 Denali Therapeutics shares in Q1 2021, an estimated $377.
  • Axiom Investment Management first reported a position in Denali Therapeutics in Q4 2020 and held it in 1 quarter.
  • Axiom Investment Management's Denali Therapeutics position peaked at $377 in Q4 2020.
  • 216 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2021.

Based on Axiom Investment Management's 13F filing for Q1 2021, filed 13 May 2021.